Despite the improved clinical responses obtained with purine analogs, chronic lymphocytic leukemia (CLL) remains incurable with available treatments [1] . Until recently, patients with CLL have generally not been considered eligible for autologous or allogeneic stem transplantation (SCT). The disease primarily effects the elderly, and the marrow is heavily involved with malignant cells; in addition available chemotherapy could not produce bone marrow remissions that would allow collection of normal autologous marrow. A number of recent developments have allowed consideration of SCT for patient with CLL. Fludarabine has been established as an effective agent that produces a true complete remission rate of 35% in previously untreated patients [2] , allowing autologous marrow or blood stem cell harvest for transplantation. Techniques for depletion of malignant leukemia cells have become available to deplete residual leukemia cells present in the autologous marrow. Finally, improved supportive care has allowed more effective and less toxic use of dose-intensive therapy in older patients. This has led to a surge in recent years in using SCT for this malignancy [3] [4] [5] [6] [7] .
Although incurable, CLL remains an indolent malignancy. Patients with early stages can live up to 10 years with their disease. This, together with the toxicity associated with SCT make it imperative to try to define guidelines of eligibility, timing of this treatment, and to quantify the cost benefit ratio. And it is in this light that we should consider the paper reported by Esteve et al. [8] in this issue of Annals of Oncology.
The authors describe the results in twelve patients with CLL who have undergone myeloblative therapy followed by allogeneic (seven patients) or autologous (five patients) SCT and in which the disease status was monitored by flowcytometry and by detection of the monoclonal rearrangement patterns of the heavy chain immunoglobulin gene by polymerase chain reaction techniques. Patients were eligible if they had Binet's stage B (six patients) or C (four patients). Patients with stage A were also eligible if they had a blood lymphocyte doubling time < 12 months or a diffuse pattern on bone marrow biopsy (two patients). Two out of seven patients (28.5%) who received allotransplant died of regimen related toxicity. Ten patients achieved CR, documented in nine by molecular methods with relatively short follow-up. The authors concluded that patients with 'highrisk' CLL, as determined by those criteria, are reasonable candidates for transplantation. However, such 'high risk' patient groups have great heterogeneity in survival.
While the feasibility and effectiveness of SCT in inducing CR is now widely accepted for CLL, guidelines regarding the timing of transplantation need to be defined. Published reports [5, 7] have demonstrated that allogeneic SCT can induce a high and durable CR rate, now up to seven years of follow-up, for patients with advanced stage CLL who were refractory to conventional chemotherapy or who failed prior fludarabine and alkylating agent therapy. The treatment related mortality and relapse rate were low (8% and 4.5% respectively).
Results from IBMTR and EBMTG have failed to show improved survival for patients transplanted in early Rai stages O-II [6] . Therefore, outside clinical trials, it is advisable to delay SCT procedures for patients who have an HLA-identical donor till later stages or in relapse after response to the best conventional treatment available. Allotransplant at this time should be considered as salvage treatment for refractory patients. The advent of lite-allotransplantation [9] using non-ablative preparative regimen is now allowing older patients to benefit from this modality of treatment with reduced toxicity. In the absence of graft-versus-leukemia effect, autologous transplantation for patients with CLL was associated with high recurrence rate (> 50%) when affected in an advanced relapse [5] . Provan et al. [10] has suggested a better outcome with autotransplant performed in first remission for patients with Binet's stages B or C. However, those patients were highly selected; they had < 2 cm lymph nodes and < 20% of the bone marrow involved; thus only 70% of the patients who were intended for transplant actually received it and it is conceivable that patients with these favorable characteristics might have done as well with conventional chemotherapy. This, however, should not necessarily imply that early transplantation should be discarded.
As a prerequisite for success in early transplantation, prognostic features have to be clearly defined. For this purpose, several prognostic factors have been evaluated which have an impact on outcome in patients with CLL; including stage, age, serum albumin level, leucocyte count, hemoglobin and platelet counts, pattern of bone marrow involvement, cytogenetics, LDH and (J2-microglobulin. In one multivariate analysis, abnormalities of chromosome 17 and elevated p2 microglobulin were the most important prognostic factors for survival [11] . The prognostic value of p2-microglobulin has been recently confirmed by two reports [12, 13] . Therefore, we suggest at this time to proceed with auto transplant in first remission for patients with those characteristics only; otherwise we propose it for patients in early first relapse, or second remission.
The finding that some patients have no minimal residual disease (MRD) detectable by polymerase chain reaction after SCT should not lure oncologists in the medical community to recommend high-dose chemotherapy at early stages. The question persists as to whether PCR status is clinically relevant surrogate endpoint in CLL. It is possible that patients may continue to harbor MRD below the limit of detection using this strategy. It is also possible that because of changes at the immunoglobulin heavy chain locus, the original patient-specific oligonucleotide probe will no longer recognize the emerging leukemic clones, as occurred in studies in acute lymphoblastic leukemia [14, 15] . For these reasons, non-ablative therapy should continue to be explored. Some new therapeutic modalities are promising; this includes cyclosporin [16] for early stage disease, campath I-H [17] , combination of fludarabine with mitoxanthrone [18] or cyclophosphamide [19] . Highdose therapy and SCT should be considered complimentary to these measures.
While it is clear that high-dose ablative therapy is providing interesting data in small groups of selected patients, clinical trials must be designed to compare efficacy with other approaches. Carefully conducted case control comparisons using established prognostic factors or randomized comparisons should prevent a proliferation of non-informative single arm studies such as have been conducted in other tumors. 
